Program
Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011
Also written as “T3011”, “T3011 high dose” and “T3011 middle dose”.
Its studies are mostly in Melanoma · Urinary Bladder Neoplasms · Carcinoma, Hepatocellular · Sarcoma · Lung Neoplasms, led by 2 companies.
Drug pageOncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ImmVira Pharmaits history only | 63 open or running | phase 2since Apr 14, 2020 | Apr 14, 2020 | Dec 31, 2028phase 2 · NCT06971614 |
| Shanghai Pharmaceuticalsits history only | 22 open or running | phase 2since Jan 9, 2024 | Jan 9, 2024 | Dec 31, 2026phase 2 · NCT06214143 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2020First study: phase 2 study in MelanomaNew to ImmVira PharmaImmVira Pharma · NCT04370587 · 30 planned · United States, Australia
- Feb 6, 2021Phase 2 study in Carcinoma, HepatocellularImmVira Pharma · NCT04780217 · 42 enrolled · United States
- Oct 18, 20222 phase 2 studiesImmVira Pharma · NCT05602792, NCT05598268
- Dec 23, 2022Phase 2 study in MelanomaImmVira Pharma · NCT05756556 · 68 enrolled · United States
- Jan 9, 2024Shanghai Pharmaceuticals’ first studies: 2 phase 2 studiesNew to Shanghai PharmaceuticalsShanghai Pharmaceuticals · NCT06214156, NCT06214143
- Apr 27, 2025Phase 2 study in Nonmuscle-invasive Bladder CancerImmVira Pharma · NCT06971614 · 160 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Advanced Solid TumorsShanghai Pharmaceuticals · NCT06214143
- Dec 31, 2028Primary completion: phase 2 study in Nonmuscle-invasive Bladder CancerImmVira Pharma · NCT06971614
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06971614Nonmuscle-invasive Bladder Cancer · United States | 2 | Recruiting | ImmVira Pharma | Dec 31, 2028 | 160 |
| NCT06214156Advanced Melanoma · China | 2 | Recruiting | Shanghai Pharmaceuticals | Sep 30, 2026 | 42 |
| NCT06214143Advanced Solid Tumors · China | 2 | Recruiting | Shanghai Pharmaceuticals | Dec 31, 2026 | 68 |
| NCT05756556Melanoma · United States | 2 | Suspended | ImmVira Pharma | Dec 31, 2026 | 68 |
| NCT05602792Sarcoma · China | 2 | UNKNOWN | ImmVira Pharma | Jul 2023 | 233 |
| NCT05598268Lung Neoplasms · China | 2 | UNKNOWN | ImmVira Pharma | Jun 2024 | 74 |
| NCT04780217Carcinoma, Hepatocellular · United States | 2 | Active, not recruiting | ImmVira Pharma | Mar 2025 | 42 |
| NCT04370587Melanoma · United States, Australia | 2 | Recruiting | ImmVira Pharma | Sep 22, 2026 | 30 |
How it is read
Names in the registry
- “T3011”, 12 entries
- “T3011 high dose”, 1 entry
- “T3011 middle dose”, 1 entry
- “T3011 low dose”, 1 entry
- “T3011 + pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 3 studies
- Urinary Bladder Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
- Sarcoma, 1 study
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.